

A Colliers In Focus Series


# Greater Boston's IPO Activity

Vol. 1, No. 27 *September 15, 2020*

Despite the economic impact resulting from COVID-19 in 2020, this has been a record year for IPO activity in Greater Boston. Boston, known to be an incubator of tech and life science companies, has seen 19 companies file for IPO and proceed to go public in the first eight months of the year. A hotbed of life science research, companies in the greater Boston area have continued to work toward solving our most pressing health challenges including research into COVID-19. Greater Boston continues to produce successful companies as it remains a leader in education, highly skilled talent, and the epicenter for life science research worldwide.

- 2020 has seen \$3.86 billion raised in IPOs thus far, already the highest single-year amount on record.
- Of the 19 IPOs this year, almost all — 14 — are for biotech or life science companies.
- Boston IPOs have outpaced those in both the Bay Area (\$2.55 billion) and Greater Chicago (\$1.24 billion) in 2020, though New York (\$9.39 billion) remains far ahead.
- IPO funding runs parallel to the record year for VC funding in Greater Boston; together totaling of over \$10 billion raised since January.
- Cambridge continues to produce public companies, with nine going public; also, six headquartered in Boston and four in the suburbs went public.
- Of the four suburban companies to go public, three are biotechs in the Life Sci-angle, the triangle between Cambridge, Lexington, and Waltham, the epicenter of the Greater Boston life science market.

## CUMULATIVE MONEY RAISED AT IPO (Billions)



A Colliers In Focus Series

Author:  
*Aaron Jodka*  
 Managing Director, Research & Client Services  
[aaron.jodka@colliers.com](mailto:aaron.jodka@colliers.com)